These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 34052717)

  • 1. Discovery of pyrrole derivatives for the treatment of glioblastoma and chronic myeloid leukemia.
    Puxeddu M; Shen H; Bai R; Coluccia A; Bufano M; Nalli M; Sebastiani J; Brancaccio D; Da Pozzo E; Tremolanti C; Martini C; Orlando V; Biagioni S; Sinicropi MS; Ceramella J; Iacopetta D; Coluccia AML; Hamel E; Liu T; Silvestri R; La Regina G
    Eur J Med Chem; 2021 Oct; 221():113532. PubMed ID: 34052717
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of (E)-N-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)-3-((3-(2-(pyridin-2-yl)vinyl)-1H-indazol-6-yl)thio)propanamide (CHMFL-ABL-121) as a highly potent ABL kinase inhibitor capable of overcoming a variety of ABL mutants including T315I for chronic myeloid leukemia.
    Liu X; Wang B; Chen C; Jiang Z; Hu C; Wu H; Zhang Y; Liu X; Wang W; Wang J; Hu Z; Wang A; Huang T; Liu Q; Wang W; Wang L; Wang W; Ren T; Li L; Xia R; Ge J; Liu Q; Liu J
    Eur J Med Chem; 2018 Dec; 160():61-81. PubMed ID: 30317026
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New 6- and 7-heterocyclyl-1H-indole derivatives as potent tubulin assembly and cancer cell growth inhibitors.
    La Regina G; Bai R; Coluccia A; Naccarato V; Famiglini V; Nalli M; Masci D; Verrico A; Rovella P; Mazzoccoli C; Da Pozzo E; Cavallini C; Martini C; Vultaggio S; Dondio G; Varasi M; Mercurio C; Hamel E; Lavia P; Silvestri R
    Eur J Med Chem; 2018 May; 152():283-297. PubMed ID: 29730191
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design, Synthesis, and Evaluation of in Vitro and in Vivo Anticancer Activity of 4-Substituted Coumarins: A Novel Class of Potent Tubulin Polymerization Inhibitors.
    Cao D; Liu Y; Yan W; Wang C; Bai P; Wang T; Tang M; Wang X; Yang Z; Ma B; Ma L; Lei L; Wang F; Xu B; Zhou Y; Yang T; Chen L
    J Med Chem; 2016 Jun; 59(12):5721-39. PubMed ID: 27213819
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel diaryl-2H-azirines: Antitumor hybrids for dual-targeting tubulin and DNA.
    Lin S; Liang Y; Cheng J; Pan F; Wang Y
    Eur J Med Chem; 2021 Mar; 214():113256. PubMed ID: 33581556
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of novel tubulin/HDAC dual-targeting inhibitors with strong antitumor and antiangiogenic potency.
    Wang Y; Sun M; Wang Y; Qin J; Zhang Y; Pang Y; Yao Y; Yang H; Duan Y
    Eur J Med Chem; 2021 Dec; 225():113790. PubMed ID: 34454126
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design, synthesis and biological evaluation of a series of pyrano chalcone derivatives containing indole moiety as novel anti-tubulin agents.
    Wang G; Li C; He L; Lei K; Wang F; Pu Y; Yang Z; Cao D; Ma L; Chen J; Sang Y; Liang X; Xiang M; Peng A; Wei Y; Chen L
    Bioorg Med Chem; 2014 Apr; 22(7):2060-79. PubMed ID: 24629450
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel tubulin polymerization inhibitor, MPT0B206, downregulates Bcr-Abl expression and induces apoptosis in imatinib-sensitive and imatinib-resistant CML cells.
    Chen CW; Lee YL; Liou JP; Liu YH; Liu CW; Chen TY; Huang HM
    Apoptosis; 2016 Sep; 21(9):1008-18. PubMed ID: 27344662
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design, synthesis, and biological evaluation of novel benzodiazepine derivatives as anticancer agents through inhibition of tubulin polymerization in vitro and in vivo.
    Pang Y; Lin H; Ou C; Cao Y; An B; Yan J; Li X
    Eur J Med Chem; 2019 Nov; 182():111670. PubMed ID: 31499359
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design, synthesis, biological evaluation and cocrystal structures with tubulin of chiral β-lactam bridged combretastatin A-4 analogues as potent antitumor agents.
    Zhou P; Liang Y; Zhang H; Jiang H; Feng K; Xu P; Wang J; Wang X; Ding K; Luo C; Liu M; Wang Y
    Eur J Med Chem; 2018 Jan; 144():817-842. PubMed ID: 29306206
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis, anticancer activity and molecular docking studies on a series of heterocyclic trans-cyanocombretastatin analogues as antitubulin agents.
    Penthala NR; Zong H; Ketkar A; Madadi NR; Janganati V; Eoff RL; Guzman ML; Crooks PA
    Eur J Med Chem; 2015 Mar; 92():212-20. PubMed ID: 25557492
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The discovery of novel indazole derivatives as tubulin colchicine site binding agents that displayed potent antitumor activity both in vitro and in vivo.
    Cui YJ; Ma CC; Zhang CM; Tang LQ; Liu ZP
    Eur J Med Chem; 2020 Feb; 187():111968. PubMed ID: 31865012
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A facile synthesis of diaryl pyrroles led to the discovery of potent colchicine site antimitotic agents.
    Romagnoli R; Oliva P; Salvador MK; Manfredini S; Padroni C; Brancale A; Ferla S; Hamel E; Ronca R; Maccarinelli F; Rruga F; Mariotto E; Viola G; Bortolozzi R
    Eur J Med Chem; 2021 Mar; 214():113229. PubMed ID: 33550186
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of 2-((3-Amino-4-methylphenyl)amino)-N-(2-methyl-5-(3-(trifluoromethyl)benzamido)phenyl)-4-(methylamino)pyrimidine-5-carboxamide (CHMFL-ABL-053) as a Potent, Selective, and Orally Available BCR-ABL/SRC/p38 Kinase Inhibitor for Chronic Myeloid Leukemia.
    Liang X; Liu X; Wang B; Zou F; Wang A; Qi S; Chen C; Zhao Z; Wang W; Qi Z; Lv F; Hu Z; Wang L; Zhang S; Liu Q; Liu J
    J Med Chem; 2016 Mar; 59(5):1984-2004. PubMed ID: 26789553
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An ent-Kaurane Diterpenoid Isolated from Rabdosia excisa Suppresses Bcr-Abl Protein Expression in Vitro and in Vivo and Induces Apoptosis of CML Cells.
    Xia Y; Feng M; Wang E; Chen L; Wang J; Hou R; Zhao Y
    Chem Biodivers; 2019 Oct; 16(10):e1900443. PubMed ID: 31468670
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MPT0B002, a novel microtubule inhibitor, downregulates T315I mutant Bcr-Abl and induces apoptosis of imatinib-resistant chronic myeloid leukemia cells.
    Yeh YY; Liou JP; Lee YL; Lin JY; Huang HM
    Invest New Drugs; 2017 Aug; 35(4):427-435. PubMed ID: 28349229
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of an indole-substituted furanone with tubulin polymerization inhibition activity.
    Mowery P; Filkorn MM; Hurysz B; Kwansare DO; Lafferty MM; McFadden MA; Neerukonda ND; Patel RR; Pierce K; Sockett KA; Truax NJ; Webster NR; Pelkey ET
    Bioorg Med Chem Lett; 2021 Jun; 41():127991. PubMed ID: 33775833
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HS-543 induces apoptosis of Imatinib-resistant chronic myelogenous leukemia with T315I mutation.
    Kim SJ; Jung KH; Yan HH; Son MK; Fang Z; Ryu YL; Lee H; Lim JH; Suh JK; Kim J; Lee S; Hong S; Hong SS
    Oncotarget; 2015 Jan; 6(3):1507-18. PubMed ID: 25483100
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery and mechanistic insights into thieno[3,2-d]pyrimidine and heterocyclic fused pyrimidines inhibitors targeting tubulin for cancer therapy.
    Wu C; Zhang L; Zhou Z; Tan L; Wang Z; Guo C; Wang Y
    Eur J Med Chem; 2024 Oct; 276():116649. PubMed ID: 38972078
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design, Synthesis, and in vitro Evaluation of Tubulin-Targeting Dibenzothiazines with Antiproliferative Activity as a Novel Heterocycle Building Block.
    Guerra WD; Lucena-Agell D; Hortigüela R; Rossi RA; Fernando Díaz J; Padrón JM; Barolo SM
    ChemMedChem; 2021 Oct; 16(19):3003-3016. PubMed ID: 34231318
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.